Literature DB >> 9792941

Interferon-induced vasospasm in chronic myeloid leukaemia.

A Zeidman1, D Dicker, M Mittelman.   

Abstract

The role of interferon (IFN) in the treatment of chronic myeloid leukaemia (CML) has been established. Many adverse effects have been reported, but vasospasm has been extremely rare. We report 2 CML patients who developed such complications. A 56-year-old female had been on IFN for 3 years with haematological and cytogenetic remission, when she developed an anginal syndrome followed by acute ischaemia. Coronary catheterization revealed normal arteries. After discontinuation of IFN her cardiac complaints disappeared and she needed no medication. A 61-year-old patient had been on IFN for 1 year when he presented with Raynaud's phenomenon. No evidence of collagen vascular disease could be documented. IFN discontinuation and intravenous administration of iloprost (a prostacyclin analogue) resulted in the disappearance of the vascular complications. IFN appears to have a beneficial effect on the course and prognosis of CML. However, we have to be aware of the potential complications and adverse effects which can be related to IFN. Neither our experience nor the literature provides convincing recommendations regarding the management of such patients. We suggest proceeding with IFN at lower doses, especially in those who have achieved a cytogenetic response, as our first patient.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9792941     DOI: 10.1159/000040874

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  5 in total

Review 1.  Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers.

Authors:  Charles Khouri; Sophie Blaise; Patrick Carpentier; Céline Villier; Jean-Luc Cracowski; Matthieu Roustit
Journal:  Br J Clin Pharmacol       Date:  2016-04-07       Impact factor: 4.335

2.  Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.

Authors:  Yvette Leung; Stefan J Urbanski; Lynn Schindel; Robert P Myers
Journal:  Can J Gastroenterol       Date:  2006-10       Impact factor: 3.522

3.  Severe Raynaud syndrome induced by adjuvant interferon alfa in metastatic melanoma.

Authors:  H Husein-Elahmed; J L Callejas-Rubio; R Ortega Del Olmo; R Ríos-Fernandez; N Ortego-Centeno
Journal:  Curr Oncol       Date:  2010-08       Impact factor: 3.677

Review 4.  Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.

Authors:  Joerg Herrmann; Eric H Yang; Cezar A Iliescu; Mehmet Cilingiroglu; Konstantinos Charitakis; Abdul Hakeem; Konstantinos Toutouzas; Massoud A Leesar; Cindy L Grines; Konstantinos Marmagkiolis
Journal:  Circulation       Date:  2016-03-29       Impact factor: 29.690

Review 5.  Common Vascular Toxicities of Cancer Therapies.

Authors:  Joerg Herrmann
Journal:  Cardiol Clin       Date:  2019-08-26       Impact factor: 2.213

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.